Skip to main content

Articles By Jack Cush, MD

RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

By Jack Cush, MD
14 January 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

By Jack Cush, MD
13 January 2022

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

By Jack Cush, MD
13 January 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Read Article
Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

By Jack Cush, MD
12 January 2022

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

By Jack Cush, MD
11 January 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

By Jack Cush, MD
11 January 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
pregnancy,doctor,consult

COVID-19 in Pregnant Rheumatic Women

By Jack Cush, MD
10 January 2022

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

Read Article
2021,year

2021 Rheumatology Year in Review

By Jack Cush, MD
08 January 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
pill pillbox adherence

Comorbidities Drive Risk of Severe Outcomes with COVID-19

By Jack Cush, MD
06 January 2022

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

By Jack Cush, MD
05 January 2022

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article
×